-
Almost Half of the Dupilumab-Treated Patients With Severe Chronic Rhinosinusitis With Nasal Polyps Achieve Remission in One Year
Otten, J. J., Elzinga, H. E., van der Lans, R. J. L., Fokkens, W. J., Reitsma, S. & PolyREG Consortium, Apr 2025, In: Allergy: European Journal of Allergy and Clinical Immunology. 80, 4, p. 1166-1168 3 p.Research output: Contribution to journal › Comment/Letter to the editor* › Academic
-
Two-Year Data of Tapered Dupilumab Shows High Effectiveness in CRSwNP With NSAID-Exacerbated Respiratory Disease
Elzinga, H. B. E., Otten, J. J., Cornet, M. E., Rinia, A. B., van der Lans, R. J. L., Fokkens, W. J., Reitsma, S. & PolyREG Consortium, 2025, (E-pub ahead of print) In: Allergy: European Journal of Allergy and Clinical Immunology.Research output: Contribution to journal › Article* › Academic › peer-review
-
More than half of chronic rhinosinusitis with nasal polyps (CRSwNP) patients treated with dupilumab experience early and fast olfactory improvement within 28 days
Otten, J. J., van der Lans, R. J. L., Elzinga, H. B. E., Adriaensen, G. F. J. P. M., Benoist, L. B. L., Hoven, R. D., Seys, S., Fokkens, W. J. & Reitsma, S., 1 Nov 2024, In: Allergy: European Journal of Allergy and Clinical Immunology. 79, 11, p. 3166-3168 3 p.Research output: Contribution to journal › Comment/Letter to the editor* › Academic
- All publications
